Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards Market

About this update from Medical Developments International Limited

[{"type":"list","items":[{"val":[{"type":"text","content":"Seasoned global pharmaceutical executive, Mr Brent MacGregor, joins Vaxxas Board to accelerate self-administered HD-MAP vaccines for global use;","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"SPRIM Global Investment’s Co-Founder and Managing Partner, Mr Michael Shleifer appointed Board Observer following recent ~$90 million financing.","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":288,"olType":false},{"type":"text","content":"BRISBANE, Australia and CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology company Vaxxas Pty Ltd, today announced the appointment of Mr Brent MacGregor as Independent Non-Executive Director to the Vaxxas Board. Mr MacGregor brings deep global experience in vaccine and medical device commercialisation to Vaxxas as the company advances its high-density microarray patch (HD-MAP) technology for self-administered vaccination towards market.","length":466,"tagName":"p"},{"type":"text","content":"Mr MacGregor is CEO of Medical Developments International (ASX: MVP), an Australian company committed to developing and distributing medicines and medical devices, including Penthrox®, known as “The Green Whistle” for acute pain, and a range of spacers for asthma and COPD (chronic obstructive pulmonary disease) sufferers. These products are marketed in more than 25 countries. He also serves on the Board of Dynavax Technologies.","length":431,"tagName":"p"},{"type":"text","content":"Prior to joining MVP, Mr MacGregor led global and regional vaccine businesses at CSL Seqirus, Novartis Vaccines and Sanofi Pasteur. With more than three decades of experience commercialising vaccines and new medical devices, across four continents, he will provide extensive insights as Vaxxas moves to commercialise the HD-MAP.","length":328,"tagName":"p"},{"type":"text","content":"OneVentures Partner and Vaxxas Chair, Ms Sarah Meibusch said the appointment provides Vaxxas with a strategic advantage as the company focuses on commercialising its HD-MAP technology platform. “Vaxxas is entering a pivotal phase; scaling manufacturing and executing the clinical pathway required to deliver a convenient, self-administered, needle-free vaccination option,” Ms Meibusch said. “Brent has built and run major vaccine businesses and understands exactly ho...

More updates from Medical Developments International Limited